Javascript must be enabled to continue!
81 Machine Learning Based Predictive Models Are More Accurate Than TNM Staging in Predicting Survival in Patients With Pancreatic Cancer
View through CrossRef
INTRODUCTION:
Accurate prognostic prediction is important for treatment planning in patients with pancreatic cancer (PC). Although clinical and socioeconomic factors impact patient survival, traditional prognostic evaluation methods [e.g., TNM staging] do not incorporate these factors. A more accurate and comprehensive tool is needed. We evaluated machine learning (ML) based analytic models to predict survival of patients with PC using data from the Surveillance, Epidemiology, End-Results (SEER) database.
METHODS:
The SEER database was accessed to identify patients aged ≥18 yr. with histologically confirmed PC diagnosed between 2004–2015. Demographic, socioeconomic, clinical variables (AJCC stage, site, grade, and size of the tumor, treatment received, survival in months) were extracted and analyzed. Using ML software, an ensemble of predictive analytic models (Classification Tree-based, Bayesian net, Neural net, support vector, and K-nearest neighbor classifier) was built and trained using supervised learning algorithms for prediction of 1-year survival probability. Separate models were built using only baseline variables (A model) and including treatment-related variables [surgery, chemotherapy, and radiotherapy (B model)].
RESULTS:
Data on 42,673 patients with PC were used to develop the predictive models [Table 1; mean age, 67 yr.; 52% males; 80% white; stage I/II/III/IV/unknown: 6.0%/27.7%/10.3%/52.5%/3.5%; median survival (range): 6 (2–13) months with 78% surviving ≤12 months]. Ten independent prognostic variables were identified in multivariate Cox regression analysis: year of diagnosis, tumor stage/grade, presence of metastasis, age, tumor size, marital status, insurance status, US region, socio-economic factors, and these variables were entered into the ML models. Figure 1 shows the predictive importance of the different variables used in the two models. AUROC (Area Under the Receiver Operating Characteristics) of the A and B models in predicting 1-year survival probability were 0.804 (95% CI: 0.800–0.808) and 0.832 (95% CI: 0.828–0.836), respectively, which were both significantly higher that of the TNM staging system (AUROC = 0.696; 95%CI: 0.691–0.700); P < 0.0001; Figure 2).
CONCLUSION:
Using advanced ML techniques for analyzing a large dataset, we developed predictive models that accurately predicted the survival of patients with PC and were superior to the existing TNM staging system. These models may serve as an effective tool for prognostic evaluation of PC in clinical settings.
Ovid Technologies (Wolters Kluwer Health)
Title: 81 Machine Learning Based Predictive Models Are More Accurate Than TNM Staging in Predicting Survival in Patients With Pancreatic Cancer
Description:
INTRODUCTION:
Accurate prognostic prediction is important for treatment planning in patients with pancreatic cancer (PC).
Although clinical and socioeconomic factors impact patient survival, traditional prognostic evaluation methods [e.
g.
, TNM staging] do not incorporate these factors.
A more accurate and comprehensive tool is needed.
We evaluated machine learning (ML) based analytic models to predict survival of patients with PC using data from the Surveillance, Epidemiology, End-Results (SEER) database.
METHODS:
The SEER database was accessed to identify patients aged ≥18 yr.
with histologically confirmed PC diagnosed between 2004–2015.
Demographic, socioeconomic, clinical variables (AJCC stage, site, grade, and size of the tumor, treatment received, survival in months) were extracted and analyzed.
Using ML software, an ensemble of predictive analytic models (Classification Tree-based, Bayesian net, Neural net, support vector, and K-nearest neighbor classifier) was built and trained using supervised learning algorithms for prediction of 1-year survival probability.
Separate models were built using only baseline variables (A model) and including treatment-related variables [surgery, chemotherapy, and radiotherapy (B model)].
RESULTS:
Data on 42,673 patients with PC were used to develop the predictive models [Table 1; mean age, 67 yr.
; 52% males; 80% white; stage I/II/III/IV/unknown: 6.
0%/27.
7%/10.
3%/52.
5%/3.
5%; median survival (range): 6 (2–13) months with 78% surviving ≤12 months].
Ten independent prognostic variables were identified in multivariate Cox regression analysis: year of diagnosis, tumor stage/grade, presence of metastasis, age, tumor size, marital status, insurance status, US region, socio-economic factors, and these variables were entered into the ML models.
Figure 1 shows the predictive importance of the different variables used in the two models.
AUROC (Area Under the Receiver Operating Characteristics) of the A and B models in predicting 1-year survival probability were 0.
804 (95% CI: 0.
800–0.
808) and 0.
832 (95% CI: 0.
828–0.
836), respectively, which were both significantly higher that of the TNM staging system (AUROC = 0.
696; 95%CI: 0.
691–0.
700); P < 0.
0001; Figure 2).
CONCLUSION:
Using advanced ML techniques for analyzing a large dataset, we developed predictive models that accurately predicted the survival of patients with PC and were superior to the existing TNM staging system.
These models may serve as an effective tool for prognostic evaluation of PC in clinical settings.
Related Results
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Abstract 1644: Pancreatic cancer survival prediction using machine learning and comparing its performance with TNM staging system and prognostic nomograms
Abstract 1644: Pancreatic cancer survival prediction using machine learning and comparing its performance with TNM staging system and prognostic nomograms
Abstract
Background:
Pancreatic cancer is one of the deadliest cancers with a 5-year survival rate of only 6%. Patients with cancer often want t...
Abstract IA-08: Clinical advances in pancreas adenocarcinoma
Abstract IA-08: Clinical advances in pancreas adenocarcinoma
Abstract
Pancreatic adenocarcinoma (PDAC) remains one of the most lethal cancers today and is expected to be the second cause of cancer death in the coming decade. M...
Selection of Injectable Drug Product Composition using Machine Learning Models (Preprint)
Selection of Injectable Drug Product Composition using Machine Learning Models (Preprint)
BACKGROUND
As of July 2020, a Web of Science search of “machine learning (ML)” nested within the search of “pharmacokinetics or pharmacodynamics” yielded over 100...
ecision Farming and Predictive Analytics in Precision Farming and Predictive Analytics in Precision Farming and Predictive Analytics in Precision Farming and Predictive Analytics in Precision Farming and Predictive Analytics in Precision Farming and Predi
ecision Farming and Predictive Analytics in Precision Farming and Predictive Analytics in Precision Farming and Predictive Analytics in Precision Farming and Predictive Analytics in Precision Farming and Predictive Analytics in Precision Farming and Predi
The scope of sensor networks and the Internet of Things spanning rapidly to diversified domains but not limited to sports, health, and business trading. In recent past, the sensors...
Frequency of Common Chromosomal Abnormalities in Patients with Idiopathic Acquired Aplastic Anemia
Frequency of Common Chromosomal Abnormalities in Patients with Idiopathic Acquired Aplastic Anemia
Objective: To determine the frequency of common chromosomal aberrations in local population idiopathic determine the frequency of common chromosomal aberrations in local population...
Abstract LB-80: Building Bridges for Pancreatic Cancer Research
Abstract LB-80: Building Bridges for Pancreatic Cancer Research
Abstract
Almost 40 years after President Nixon signed into law the National Cancer Act, the survival rate for pancreatic cancer has not substantially improved. Today...
Prognostic value of metabolic tumor volume on [18F]FDG PET/CT in addition to the TNM classification system of locally advanced non-small cell lung cancer
Prognostic value of metabolic tumor volume on [18F]FDG PET/CT in addition to the TNM classification system of locally advanced non-small cell lung cancer
Abstract
Purpose
Staging of non-small cell lung cancer (NSCLC) is commonly based on [18F]FDG PET/CT, in particular to exclude distant metastases and...

